Details for Patent: 8,987,270

Title:	Formulations of selective alpha-2 agonists and methods of use thereof
Abstract:	The invention provides compositions and methods utilizing low concentrations of selective .alpha.-2 adrenergic receptor agonists, preferably, brimonidine. The invention provides contact lens solutions and methods of using these solutions for pre-soaking contact lenses to achieve reduction of redness and/or increase in whitening of eyes. The invention also provides compositions including a selective .alpha.-2 adrenergic receptor agonist in a combination with an ocular medical device, including but not limited to a bandage lens. The invention also provides combination compositions including a selective .alpha.-2 adrenergic receptor agonist and another active agent for the treatment of an ocular condition, including but not limited to glaucoma and/or a condition associated with eye redness.
Inventor(s):	Horn; Gerald (Deerfield, IL)
Assignee:	Eye Therapies LLC (Dana Point, CA)
Filing Date:	Sep 07, 2012
Application Number:	13/606,637
Claims:	1. A method of reducing eye redness, wherein said method consists essentially of inserting a contact lens in a solution consisting essentially of brimonidine or a pharmaceutically acceptable salt thereof, wherein said brimonidine is present at a concentration from between about 0.001% to about 0.05% weight by volume, and wherein said solution has a pH of between about 4.0 and about 6.5, and then inserting said contact lens into an eye. 2. The method of claim 1, wherein said brimonidine is at a concentration from between about 0.01% to about 0.025% weight by volume.